Dexibuprofen - NSAIDs Agents- (FDC - List ) (Feb 2006)
Drug Name:Dexibuprofen - NSAIDs Agents- (FDC - List ) (Feb 2006)
List Of Brands:
Indication Type Description:
Drug Interaction
Indication
Adverse Reaction
Contra-Indications
Dosages/ Overdosage Etc
Pharmacology/ Pharmacokinetics
Interaction with Food
Pregnancy and lactation
Drug Interaction:
Concomiitant use of dexibuprofen is not recommended with the following drugs because of drug - interactions Anticoagulants Lthium Other NSAIDs & aspirin
Indication:
Symptomatic treatment of pain & infalmmation associated with osteoarthiritis
Adverse Reaction:
Common advese reactions were dyspepsia, diarrhea, fatigue, or drowsiness, headache, dizziness vertigo.
Peripheral odema GI adverse effects are less than that of ibuprofen and celocixib In long rtem study, adverse drug events were 15.2%
Racemic ibuprofen showed a 30% and diclofenac a 90% higher incidence of adverse reactions than dexibuprofen
Contra-Indications:
Hypersensitivity to dexibuprofen to any other NSAID or to any of the excepients Active or suspected gastrointestiunal ulcer or history of recurrent gastrointestinal ulcer Gastrointestinal bleeding or other active bleedings or bleeding disorders.
Active Chrohns disease or active ulcerative colitis Severe heart failure Severe impaired hepatic function Haemorrhage diathesis & other coagulation disorders or patients receiving anticoagulant therapy Second trimester pregnancy
Precautions-
Administered with caution in patients with past history of serious cardiocascular thrombotic events, severe liver liver dysfunction, severe renal failure Patients with active or suspected gastrointestinal ulcer or history of recurrent gastrointestinal ulcer.
Elderly or debilated patients and in pregnancy
History of allergic rhibitis or bronchial asthma
Dosages/ Overdosage Etc:
Indication-
Symptomatic treatment of pain & infalmmation associated with osteoarthiritis
Dosage-
Maximum single dosage is 400mg dexibuprufen
Dose may be increased up to 1200 mg dexibuprofen per day in pts with acute conditions or exacerbations
Maximum daily dose is 1200mg In case of mild to moderate hepatic conditions
Pharmacology/ Pharmacokinetics:
Pharmacology
Mechanism of action- Dexibuprofen inhibits prostagladin synthesis and formation of thromboxanes voia blockade of cytogenase (COX) enzymes. Dexibuprofen inhibits both COX-1 and COX-2 with somewhat lower potency for COX-2
Pharmacokinetics
Dexibuprofen is absorbed rapidly Reaches maximum concentrations of 12.4 microg/ml after 200mg respy. 12 microg/ml 400mg dose adjusted Time taken to reach maximum conc is tmax 2.1 to 2.2 hours Shows linear dose-relatonship Plasma protein binding is about 99%
Metablic transformation takes place in the liver (hydroxylation,carboxylation) Pharmacologically inactive metabolites are completely excreted mainly by the kidneys but also in bile.
The elimination half-life is 1.8- 3.5 hrs Admin of dexibuprofen with meal delays the time to reach max conc from 2.1 hours (after fasting conditions to 2.8 hours. After non-fasting conditions) and decreases the max plasma conc (from 20.6 to 18.1 ug/ml which is of no clinical relavance) but has no effect on the extent of absorption
Interaction with Food:
Admin of dexibuprofen with meal delays the time to reach max conc from 2.1 hours (after fasting conditions to 2.8 hours fter non-fasting conditions) and decreases the max plasma conc (from 20.6 to 18.1 ug/ml which is of no clinical relavance) but has no effect on the extent of absorption
Pregnancy and lactation:
Pregnancy
Use of Dexiboprofen is not recommended in women attempting to conceive. No clinical data on exposed pregnancies are available for Dexibuprofen. The potential for human risk in pregnancy is unknown.
Lactation
Pharmacokinetics of Dexibuprofen has not been studied in lactating women and its administration is not recommended Children- Pharmacokinetics of Dexibuprofen has not been studied in peditric population and its administration is not recommended in pediatric patients
Elderly-
Pharmacokinetics of Dexibuprofen has not been studied in geriatric population and its administration is not recommended in Geriatric patients